Loading
Evofem Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by PELLETIER SAUNDRA L, was filed 31 May 2022.
Insider Decl.
197
Thresholds
n/a
Buy Volume
€50M
36 ops. · all time
Sell Volume
€33M
37 ops. · all time
Since the insiders bought
- -97.8%Entry US$43.38 · Close at T+365 US$0.96
- -98.8%Entry US$811.88 · Close at T+365 US$9.75
- -98.8%Entry US$811.88 · Close at T+365 US$9.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.01
Analyst consensus
Income statement
RevenueUS$20.2M
Gross profitUS$15.6M77% margin
EBITDAUS$2.1M10% margin
Net incomeUS$274k-84.7% margin
Valuation
Beta-1.36
Balance sheet & cash
Total debtUS$54.5M
Free Cash Flow-US$2M
Profitability & ownership
ROA-26.8%
% insiders0.0%
% institutions0.0%
Last declaration on 12 January 2024
Declarations197 total
104 shares@ US$0.0385100.0% of flowCommon StockSEC:0001493152-24-002231:0
10 shares@ US$0.621100.0% of flowCommon StockSEC:0001493152-23-045912:0
50,000 shares0Common StockSEC:0001251371-23-000002:0
141,000 shares@ US$0.352522.3% of flowCommon StockSEC:0001618835-22-000130:0
Canonical exit: 25 Aug 2022 (T+90)
750,000 shares0Common StockSEC:0001618835-22-000028:0
300,000 shares0Common StockSEC:0001618835-22-000031:0
450,000 shares0Common StockSEC:0001618835-22-000030:0
120,000 shares0Common StockSEC:0001618835-22-000006:0
300,000 shares0Common StockSEC:0001618835-22-000004:0
120,000 shares0Common StockSEC:0001618835-22-000005:0
40,594 shares@ US$0.3720.9% of flowCommon StockSEC:0001618835-21-000272:0
Canonical exit: 20 Mar 2022 (T+90)
25,000 shares@ US$0.38918.5% of flowCommon StockSEC:0001618835-21-000273:0
Canonical exit: 20 Mar 2022 (T+90)
135,000 shares@ US$0.37521.7% of flowCommon StockSEC:0001618835-21-000271:0
Canonical exit: 20 Mar 2022 (T+90)
19,998 shares@ US$0.97529.6% of flowCommon StockSEC:0001618835-21-000158:0
10,000 shares@ US$1.165100.0% of flowCommon StockSEC:0001618835-21-000156:0
Canonical exit: 16 Sept 2021 (T+90)
8,140 shares@ US$1.31100.0% of flowCommon StockSEC:0001618835-21-000153:0
Canonical exit: 12 Sept 2021 (T+90)
5,000 shares@ US$1.198100.0% of flowCommon StockSEC:0001618835-21-000154:0
Canonical exit: 9 Sept 2021 (T+90)
18,180 shares@ US$1.1430.6% of flowCommon StockSEC:0001618835-21-000150:0
Canonical exit: 9 Sept 2021 (T+90)
24,500 shares@ US$1.0332.5% of flowCommon StockSEC:0001618835-21-000148:0
Canonical exit: 8 Sept 2021 (T+90)
50,000 shares@ US$1.0320.4% of flowCommon StockSEC:0001618835-21-000147:0
Canonical exit: 8 Sept 2021 (T+90)
10,000 shares@ US$1.02518.0% of flowCommon StockSEC:0001618835-21-000146:0
Canonical exit: 8 Sept 2021 (T+90)
105,300 shares@ US$0.8635.7% of flowCommon StockSEC:0001618835-21-000133:0
42,061 shares@ US$0.86100.0% of flowCommon StockSEC:0001618835-21-000135:0
31,480 shares@ US$0.8639.8% of flowCommon StockSEC:0001618835-21-000136:0
42,280 shares@ US$0.8646.6% of flowCommon StockSEC:0001618835-21-000134:0
25 of 197 declarations
About Evofem Biosciences, Inc.
At Evofem Biosciences, Inc., a US healthcare and pharma company listed on Nasdaq, purchases outnumber sales: 33 against 24, or 58% purchases among open-market trades. The 14 purchases with an amount total EUR 225,332 with a median of EUR 9,288; the three largest are by Saundra L. Pelletier, Chief Executive Officer: EUR 46,308 on May 27, 2022, EUR 45,026 on December 20, 2021 and EUR 42,308 on June 10, 2021.
The sales carry token amounts: 12 have an amount, EUR 62 in all, and the largest are EUR 7 for Kelly Culwell, Chief Medical Officer, on December 2, 2019, then EUR 6 for the same filer on February 19, 2020, and EUR 6 for Russell Barrans, Chief Commercial Officer, on January 16, 2020. From June 10 to June 18, 2021, seven insiders filed purchases worth EUR 111,982. Across the full history, 10 purchase filings are classed as clustered.
Read moreShow less
The record holds 152 filings published from June 23, 2016 to January 12, 2024, from 16 filers, 82 of them grants. Saundra L. Pelletier files 28 times, Justin J. File 26 and Russell Barrans 26. The year 2020 is the fullest, with 52 filings. For 14 purchases a 90-day result is stored: a median of minus 20.6%, with 21% of results positive, recorded past results, not a forecast.
